更正“人KAT2A (GCN5)组蛋白乙酰转移酶与SARS-CoV-2 Orf8病毒蛋白的比对”

Q1 Medicine
{"title":"更正“人KAT2A (GCN5)组蛋白乙酰转移酶与SARS-CoV-2 Orf8病毒蛋白的比对”","authors":"","doi":"10.1002/cdt3.70002","DOIUrl":null,"url":null,"abstract":"<p>S. Lehrer and P. H. Rheinstein, “Alignment of Human KAT2A (GCN5) Histone Acetyltransferase and SARS-CoV-2 Orf8 Viral Proteins,” <i>Chronic Diseases and Translational Medicine</i> 9 (2023): 263–265. https://doi.org/10.1002/cdt3.56.</p><p>The original article included a Conflict of Interest statement which stated: “The authors declare no conflicts of interest.” The journal and the publisher have determined that a conflict of interest on behalf of each author was not declared at publication. The journal and the publisher have had sufficient communication with the authors via email after raising questions about the Conflict of Interest in the article. The authors declared that there was no undeclared Conflict of Interest and further stated that their individual affiliations with commercial entities did not influence the research findings. Following further correspondence between the publisher and the authors, all parties have agreed to include the following Conflicts of Interest statement with the published article:</p><p>Steven Lehrer serves in a scientific advisory capacity with Fermata Pharma Inc. Peter H. Rheinstein is President of Severn Health Solutions. The scientific content was developed without influence from Fermata Pharma Inc. or Severn Health Solutions.</p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70002","citationCount":"0","resultStr":"{\"title\":\"Correction to “Alignment of Human KAT2A (GCN5) Histone Acetyltransferase and SARS-CoV-2 Orf8 Viral Proteins”\",\"authors\":\"\",\"doi\":\"10.1002/cdt3.70002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>S. Lehrer and P. H. Rheinstein, “Alignment of Human KAT2A (GCN5) Histone Acetyltransferase and SARS-CoV-2 Orf8 Viral Proteins,” <i>Chronic Diseases and Translational Medicine</i> 9 (2023): 263–265. https://doi.org/10.1002/cdt3.56.</p><p>The original article included a Conflict of Interest statement which stated: “The authors declare no conflicts of interest.” The journal and the publisher have determined that a conflict of interest on behalf of each author was not declared at publication. The journal and the publisher have had sufficient communication with the authors via email after raising questions about the Conflict of Interest in the article. The authors declared that there was no undeclared Conflict of Interest and further stated that their individual affiliations with commercial entities did not influence the research findings. Following further correspondence between the publisher and the authors, all parties have agreed to include the following Conflicts of Interest statement with the published article:</p><p>Steven Lehrer serves in a scientific advisory capacity with Fermata Pharma Inc. Peter H. Rheinstein is President of Severn Health Solutions. The scientific content was developed without influence from Fermata Pharma Inc. or Severn Health Solutions.</p>\",\"PeriodicalId\":32096,\"journal\":{\"name\":\"Chronic Diseases and Translational Medicine\",\"volume\":\"11 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70002\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chronic Diseases and Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cdt3.70002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronic Diseases and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cdt3.70002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

李春华,李春华,李春华,等,“人类KAT2A (GCN5)组蛋白乙酰转移酶与SARS-CoV-2病毒Orf8蛋白的序列分析”,中国生物医学工程学报9(2023):263-265。https://doi.org/10.1002/cdt3.56.The原文包含利益冲突声明:“作者声明无利益冲突。”期刊和出版商已经确定,在发表时没有声明代表每位作者的利益冲突。在对文章中的利益冲突提出质疑后,期刊和出版商已经通过电子邮件与作者进行了充分的沟通。作者声明不存在未申报的利益冲突,并进一步表示他们与商业实体的个人关系不会影响研究结果。根据出版商和作者之间的进一步通信,所有各方都同意在发表的文章中包含以下利益冲突声明:Steven Lehrer在Fermata Pharma Inc.担任科学顾问。Peter H. Rheinstein是Severn Health Solutions的总裁。科学内容的开发不受Fermata Pharma Inc.或Severn Health Solutions的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Correction to “Alignment of Human KAT2A (GCN5) Histone Acetyltransferase and SARS-CoV-2 Orf8 Viral Proteins”

S. Lehrer and P. H. Rheinstein, “Alignment of Human KAT2A (GCN5) Histone Acetyltransferase and SARS-CoV-2 Orf8 Viral Proteins,” Chronic Diseases and Translational Medicine 9 (2023): 263–265. https://doi.org/10.1002/cdt3.56.

The original article included a Conflict of Interest statement which stated: “The authors declare no conflicts of interest.” The journal and the publisher have determined that a conflict of interest on behalf of each author was not declared at publication. The journal and the publisher have had sufficient communication with the authors via email after raising questions about the Conflict of Interest in the article. The authors declared that there was no undeclared Conflict of Interest and further stated that their individual affiliations with commercial entities did not influence the research findings. Following further correspondence between the publisher and the authors, all parties have agreed to include the following Conflicts of Interest statement with the published article:

Steven Lehrer serves in a scientific advisory capacity with Fermata Pharma Inc. Peter H. Rheinstein is President of Severn Health Solutions. The scientific content was developed without influence from Fermata Pharma Inc. or Severn Health Solutions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.70
自引率
0.00%
发文量
195
审稿时长
35 weeks
期刊介绍: This journal aims to promote progress from basic research to clinical practice and to provide a forum for communication among basic, translational, and clinical research practitioners and physicians from all relevant disciplines. Chronic diseases such as cardiovascular diseases, cancer, diabetes, stroke, chronic respiratory diseases (such as asthma and COPD), chronic kidney diseases, and related translational research. Topics of interest for Chronic Diseases and Translational Medicine include Research and commentary on models of chronic diseases with significant implications for disease diagnosis and treatment Investigative studies of human biology with an emphasis on disease Perspectives and reviews on research topics that discuss the implications of findings from the viewpoints of basic science and clinical practic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信